Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, Mansi; Marron, Thomas U.; Kodysh, Julia; Finnigan, John P.; Onkar, Sayali; Kaminska, Anna; Tuballes, Kevin; Guo, Ruiwei; Sabado, Rachel Lubong; Meseck, Marcia; O’Donnell, Timothy J.; Sebra, Robert P.; Parekh, Samir; Galsky, Matthew D.; Blasquez, Ana; Gimenez, Gustavo; Bicak, Mesude; Cimen Bozkus, Cansu; Delbeau-Zagelbaum, Daniela; Rodriguez, Denise; Acuna-Villaorduna, Ana; Misiukiewicz, Krzysztof J.; Posner, Marshall R.; Miles, Brett A.; Irie, Hanna Y.; Tiersten, Amy; Doroshow, Deborah B.; Wolf, Andrea; Mandeli, John; Brody, Rachel; Salazar, Andres M.; Gnjatic, Sacha; Hammerbacher, Jeff; Schadt, Eric; Friedlander, Philip; Rubinsteyn, Alexander; Bhardwaj, Nina

doi:10.1158/2159-8290.28918013

Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

journal contribution

posted on 2025-05-02, 07:22 authored by Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’Donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj

Supplementary Table2 – Variant count per patient

Funding

Lake Champlain Cancer Research Organization

Parker Institute for Cancer Immunotherapy (PICI)

History

ARTICLE ABSTRACT

The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.